

CORRECTION

Open Access



# Correction: hOA-DN30: a highly effective humanized single-arm MET antibody inducing remission of 'MET-addicted' cancers

Ilaria Martinelli<sup>1</sup>, Chiara Modica<sup>1</sup>, Cristina Chiriaco<sup>1</sup>, Cristina Basilico<sup>1</sup>, James M. Hughes<sup>1</sup>, Simona Corso<sup>1,2</sup>, Silvia Giordano<sup>1,2</sup>, Paolo M. Comoglio<sup>1</sup> and Elisa Vigna<sup>1,2\*</sup> 

**Correction: J Exp Clin Cancer Res 41, 112 (2022)**  
<https://doi.org/10.1186/s13046-022-02320-6>

#### Author details

<sup>1</sup>Candiolo Cancer Institute, FPO-IRCCS, Strada Provinciale 142, 10060 Candiolo, TO, Italy. <sup>2</sup>Department of Oncology, University of Turin, Turin, Italy.

Following publication of the original article [1], author would like to correct the Funding section statement.

#### Incorrect Funding:

This research was funded by Fondazione AIRC under 5 per Mille 2018 – ID 21052 program - PI: Comoglio PM, GL: Vigna E; by FPRC 5xmille 2014 Ministero Salute to PMC, and by Ministero Salute, Ricerca Corrente 2018–2020. The studies performed by Accelera Srl. were sponsored by Metis Precision Medicine B-Corp.

#### Correct Funding:

This research was funded by Fondazione AIRC under 5 per Mille 2018 - ID 21052 program - PI: Comoglio PM, GL: Vigna E; **by Italian Association for Cancer Research (AIRC), IG 20210 to S. Giordano, and IG 21770 to S. Corso**; by FPRC 5xmille 2014 Ministero Salute to PMC, and by Ministero Salute, Ricerca Corrente 2018-2020. The studies performed by Accelera Srl. were sponsored by Metis Precision Medicine B-Corp.

The correction does not have any effect on the final conclusions of the paper. The original article has been corrected.

Published online: 24 May 2022

#### Reference

1. Martinelli I, Modica C, Chiriaco C, et al. hOA-DN30: a highly effective humanized single-arm MET antibody inducing remission of 'MET-addicted' cancers. *J Exp Clin Cancer Res*. 2022;41:112. <https://doi.org/10.1186/s13046-022-02320-6>.

The original article can be found online at <https://doi.org/10.1186/s13046-022-02320-6>.

\*Correspondence: [e.vigna@unito.it](mailto:e.vigna@unito.it)

<sup>2</sup> Department of Oncology, University of Turin, Turin, Italy  
Full list of author information is available at the end of the article



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.